Syngene International Ltd - SYNGENE INTL. Share Price

Sector: Pharmaceuticals | ISIN: INE398R01022
₹ 718.60 (1.40%) icon19 Apr, 2024, 1:44:55 PM
Open
₹ 702.25
Prev. Close
₹ 708.65
Turnover(lac)
₹ 0.03
Day's High
₹ 720.00
Day's Low
₹ 696.50
52 Wk High
₹ 860.25
52 Wk Low
₹ 610.10
Book Value
₹ 96.92
Face Value
₹ 10.00
Mkt. Cap (Cr.)
₹ 28,888.80
P/E
59.98
EPS
11.80
Div. Yield
0.18

Syngene International Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 4/19/2024 1:44:55 PM

    ₹ 718.6 9.95 1.40
  • Open
  • ₹ 702.25
  • Prev. Close
  • ₹ 708.65
  • Turnover(Lac.)
  • ₹ 0
  • Day's High
  • ₹ 720
  • Day's Low
  • ₹ 696.5
  • 52 Week's High
  • ₹ 860.25
  • 52 Week's Low
  • ₹ 610.1
  • Book Value
  • ₹ 96.92
  • Face Value
  • ₹ 10
  • Mkt Cap (₹ Cr.)
  • 28,888.8
  • P/E
  • 59.98
  • EPS
  • 11.8
  • Divi. Yield
  • 0.18

Syngene International Ltd Corporate Actions

26 Dec , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

26 Dec , 2023

12:00 AM

06 Oct , 2023

12:00 AM

06 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

13 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

13 Jul , 2023

12:00 AM

26 Apr , 2023

12:00 AM

AGM

Announcement date: 26 Apr , 2023

View Details

26 Apr , 2023

12:00 AM

Dividend

Dividend amount: 0.5
Announcement date: 26 Apr , 2023

View Details

26 Apr , 2023

12:00 AM

Dividend

Dividend amount: 0.75
Announcement date: 26 Apr , 2023

View Details

07 Apr , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

07 Apr , 2023

12:00 AM

No Record Found


Syngene International Ltd News and Update

Image not found

ICRA put Syngene's facilities ratings on watch following the rating action on the debt facilities of the holding Company, Biocon Ltd.

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Syngene International Ltd SHAREHOLDING SNAPSHOT
19 April , 2024 | 02:01 PM

PROMOTER - TOTAL54.79%

Indian: 54.79%

Foreign: 0.0034%

NON-PROMOTER - TOTAL 44.89%

Institutions: 35.83%

Non-Institutions: 9.05%

CUSTODIES - 0.32%

Custodies: 0.32%

See More Details
ad IconAd Image

Syngene International Ltd FINANCIALS

Syngene International Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Syngene International Ltd

  • Kiran Mazumdar Shaw
  • Chairperson
  • Catherine Patricia Rosenberg
  • Director
  • Paul Frederick Blackburn
  • Independent Director
  • Vijay Kuchroo
  • Independent Director
  • Jonathan Hunt
  • Managing Director & CEO
  • Vinita Bali
  • Lead Independent Director
  • Priyadarshnini Mahapatra
  • Company Sec. & Compli. Officer
  • Sharmila Karve
  • Independent Director
  • Carl Decicco
  • Director
  • Kush Parmar
  • Independent Director

Summary

Syngene International Limited is an integrated research, development and manufacturing services organization serving global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Headquartered in India, the operations are driven by its highly qualified teams comprising ~6000 scientists and its state-of-the-art facilities, spread over 2.2 million sq. ft., across 3 locations in India: Bangalore, Hyderabad and Mangalore. The Company operate into 4 business divisions comprising of Discovery Services, Development Services, Manufacturing Services and the Dedicated Centers.The Company was promoted by Biocon and Kiran Mazumdar Shaw, a promoter of Biocon Limited. The Companys health-related services extend across all major therapeutic areas and modalities. It provides end-to-end services within the Contract Research Organization (CRO) and a growing range of services within the Contract Development and Manufacturing Organization (CDMO). The primary target market for these services is the pharmaceutical and biotechnology (biotech) sectors. The same scientific capabilities that serve human health also serve nutrition, animal health, consumer goods, agri-chemicals, and specialty chemical sectors.Syngene International Limited was incorporated at Bangalore in the year 1993. During the year 1994-1995, the company pioneered in CRO services for both Chemistry and Biology. During the year 2001-2002, the company acquired a new facility inclusive... Read More


Reports by Syngene International Ltd


Reports by Syngene International Ltd

Company FAQ

No Record Found